JP2013531801A - 標的検出のためのハプテンコンジュゲート - Google Patents

標的検出のためのハプテンコンジュゲート Download PDF

Info

Publication number
JP2013531801A
JP2013531801A JP2013518768A JP2013518768A JP2013531801A JP 2013531801 A JP2013531801 A JP 2013531801A JP 2013518768 A JP2013518768 A JP 2013518768A JP 2013518768 A JP2013518768 A JP 2013518768A JP 2013531801 A JP2013531801 A JP 2013531801A
Authority
JP
Japan
Prior art keywords
hapten
conjugate
antibody
peroxidase
subsequent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531801A5 (enExample
Inventor
アドリアン， イー． ムリーリョ，
ジェローム， ダブリュ． コスメーダー，
エリック メイ，
ウィリアム デイ，
マーク ラフィーバー，
アン， エム． ペダータ，
クリストファー ビーニアーツ，
フィリップ ミラー，
Original Assignee
ヴェンタナ メディカル システムズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェンタナ メディカル システムズ， インク． filed Critical ヴェンタナ メディカル システムズ， インク．
Publication of JP2013531801A publication Critical patent/JP2013531801A/ja
Publication of JP2013531801A5 publication Critical patent/JP2013531801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013518768A 2010-07-02 2011-07-01 標的検出のためのハプテンコンジュゲート Pending JP2013531801A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39894610P 2010-07-02 2010-07-02
US61/398,946 2010-07-02
US201161464216P 2011-02-28 2011-02-28
US61/464,216 2011-02-28
PCT/US2011/042849 WO2012003476A2 (en) 2010-07-02 2011-07-01 Hapten conjugates for target detection

Publications (2)

Publication Number Publication Date
JP2013531801A true JP2013531801A (ja) 2013-08-08
JP2013531801A5 JP2013531801A5 (enExample) 2014-07-17

Family

ID=44583735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518768A Pending JP2013531801A (ja) 2010-07-02 2011-07-01 標的検出のためのハプテンコンジュゲート

Country Status (6)

Country Link
US (1) US20130109019A1 (enExample)
EP (1) EP2588443A2 (enExample)
JP (1) JP2013531801A (enExample)
AU (1) AU2011274369A1 (enExample)
CA (1) CA2800936A1 (enExample)
WO (1) WO2012003476A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514214A (ja) * 2012-03-27 2015-05-18 ヴェンタナ メディカル システムズ， インク． シグナリングコンジュゲート及び使用法
JP2017158497A (ja) * 2016-03-10 2017-09-14 コニカミノルタ株式会社 Ｆｉｓｈ染色方法
WO2017175523A1 (ja) * 2016-04-06 2017-10-12 コニカミノルタ株式会社 蛍光免疫染色法
JPWO2016147825A1 (ja) * 2015-03-13 2017-12-28 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
JP2018536163A (ja) * 2015-11-22 2018-12-06 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１陽性腫瘍組織における免疫細胞を同定する方法
JP2020514701A (ja) * 2016-12-19 2020-05-21 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022500657A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本
JP2023538753A (ja) * 2020-08-28 2023-09-11 ヴェンタナ メディカル システムズ， インク． 検出可能な部分を含むコンジュゲート

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
EP2542883B1 (en) 2010-03-04 2019-10-02 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
EP2588144B1 (en) 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
WO2014139980A1 (en) * 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
EP3764084A1 (en) 2013-03-12 2021-01-13 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
JP6483082B2 (ja) 2013-03-15 2019-03-13 ジェネンテック， インコーポレイテッド Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法
CA2899158C (en) * 2013-03-15 2021-05-04 Ventana Medical Systems, Inc. Spectral unmixing
CN110669826B (zh) * 2013-04-30 2025-01-07 加州理工学院 通过顺序杂交编条形码的分子多重标记
ES2729638T3 (es) * 2013-10-11 2019-11-05 Ventana Med Syst Inc Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral
EP3617322A1 (en) 2014-02-24 2020-03-04 Ventana Medical Systems, Inc. Automated rna detection using labeled 2 -o-methyl rna oligonucleotide probes and signal amplification systems
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
EP3309174B1 (en) 2014-07-11 2022-05-11 Ventana Medical Systems, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
ES2791950T3 (es) 2015-02-03 2020-11-06 Ventana Med Syst Inc Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
CN108449995B (zh) 2015-11-06 2022-02-01 文塔纳医疗系统公司 代表性诊断
JP6876062B2 (ja) 2016-01-26 2021-05-26 ヴェンタナ メディカル システムズ， インク． 自動ダイセクション、次世代シークエンシング、及び自動スライド染色装置を用いる、腫瘍のための予測診断ワークフロー
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
JP7021126B2 (ja) 2016-06-28 2022-02-16 ヴェンタナ メディカル システムズ， インク． マルチ色素キノンメチド及びチラミドコンジュゲートによる発色性ｉｈｃ及びｉｓｈ染色のための新規の色
CN110073218A (zh) 2016-09-23 2019-07-30 文塔纳医疗系统公司 用于对肿瘤样品中的细胞外基质生物标志物评分的方法和系统
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
JP7038209B2 (ja) 2017-11-13 2022-03-17 エフ．ホフマン－ラ ロシュ アーゲー エピタコ電気泳動を使用する試料分析のための装置
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
WO2019224153A1 (en) 2018-05-21 2019-11-28 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
CN108957017A (zh) * 2018-05-29 2018-12-07 郑州左安检测科技有限公司 一种检测苯二氮卓的试纸条及其制备方法和应用方法
CN108918896A (zh) * 2018-05-29 2018-11-30 郑州左安检测科技有限公司 一种检测苯二氮卓的fitc试纸条及其制备方法和应用方法
WO2020016266A1 (en) 2018-07-17 2020-01-23 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
EP3850367B1 (en) 2018-09-13 2024-11-06 Ventana Medical Systems, Inc. Histochemical and cytochemical methods for detecting ntrk fusion proteins
EP3861556A1 (en) 2018-10-01 2021-08-11 Ventana Medical Systems, Inc. Methods and systems for predicting response to pd-1 axis directed therapeutics
EP3864403A1 (en) 2018-10-12 2021-08-18 F. Hoffmann-La Roche AG Detection methods for epitachophoresis workflow automation
CN113348356A (zh) 2018-11-20 2021-09-03 文塔纳医疗系统公司 用于针对形态学特征和生物标志物表达而制备和分析细胞样品的方法和系统
WO2020161125A1 (en) 2019-02-05 2020-08-13 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
EP4147054A1 (en) 2020-05-07 2023-03-15 Ventana Medical Systems, Inc. Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples
JP2023544113A (ja) 2020-09-22 2023-10-20 エフ． ホフマン－ラ ロシュ アーゲー α－１，６－コア－フコシル化ＰＳＡ及びそのフコシル化断片に特異的な抗体
CN113552362B (zh) * 2021-07-23 2024-08-09 湖北百奥斯生物科技有限公司 一种新型信号放大的免疫荧光试剂盒
CN116444424B (zh) * 2023-06-16 2023-09-08 广东省大湾区华南理工大学聚集诱导发光高等研究院 一种基于聚集诱导发光的酪酰胺荧光材料、免疫组化染色试剂盒及其应用
WO2025014787A1 (en) 2023-07-07 2025-01-16 Ventana Medical Systems, Inc. Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933355A1 (en) * 1997-12-24 1999-08-04 Universiteit Maastricht Preparation of tyramide conjugates
JP2008228637A (ja) * 2007-03-20 2008-10-02 Tokushima Bunri Univ 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法
JP2008298654A (ja) * 2007-05-30 2008-12-11 Ventana Medical Systems Inc バイオマーカーの多色発色検出
JP2010508532A (ja) * 2006-11-01 2010-03-18 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
EP0314725A1 (en) * 1987-05-19 1989-05-10 FISONS plc 2-(3,4-dihydroxyphenyl)ethylamines, their preparation and use as pharmaceutical
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5455143A (en) * 1991-10-25 1995-10-03 Minnesota Mining And Manufacturing Company Aminoketone sensitizers for aqueous soluble photopolymer compositions
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6372937B1 (en) 1998-11-09 2002-04-16 Mark Norman Bobrow Enhanced catalyzed reporter deposition
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
CN1167697C (zh) * 1999-09-17 2004-09-22 日产化学工业株式会社 苯并吡喃衍生物
US6630469B2 (en) * 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
US6914069B2 (en) * 2000-05-19 2005-07-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active compounds and methods of use
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
ATE556845T1 (de) 2001-07-20 2012-05-15 Life Technologies Corp Lumineszierende nanopartikel und ihre herstellung
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7981667B2 (en) 2003-05-07 2011-07-19 Indiana University Research And Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP4411153B2 (ja) * 2003-07-18 2010-02-10 富士フイルム株式会社 ２光子吸収色素消色材料、３次元的屈折率変調材料、３次元吸収率変調材料及び３次元光記録材料
KR100657891B1 (ko) 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
JP4537407B2 (ja) * 2003-10-30 2010-09-01 ベーリンガー インゲルハイム （カナダ） リミテッド Ｒｓｖポリメラーゼインヒビター
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20060246423A1 (en) 2005-02-10 2006-11-02 Adelson Martin E Method and kit for the collection and maintenance of the detectability of a plurality of microbiological species in a single gynecological sample
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
EP2421833B1 (en) * 2009-04-21 2015-01-14 Nerviano Medical Sciences S.r.l. Resorcinol derivatives as hsp90 inhibitors
EP2588144B1 (en) * 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933355A1 (en) * 1997-12-24 1999-08-04 Universiteit Maastricht Preparation of tyramide conjugates
JP2010508532A (ja) * 2006-11-01 2010-03-18 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
JP2008228637A (ja) * 2007-03-20 2008-10-02 Tokushima Bunri Univ 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法
JP2008298654A (ja) * 2007-05-30 2008-12-11 Ventana Medical Systems Inc バイオマーカーの多色発色検出

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"TYRAMIDE SIGNAL AMPLIFICATION (TSA) TECHNOLOGY", HANDBOOK OF FLUORESCENT PROBES AND RESEARCH PRODUCTS, 9TH ED., [ONLINE], JPN5013008461, 1 January 2002 (2002-01-01), ISSN: 0003012414 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10041950B2 (en) 2012-03-27 2018-08-07 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
US11906523B2 (en) 2012-03-27 2024-02-20 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
JP2015514214A (ja) * 2012-03-27 2015-05-18 ヴェンタナ メディカル システムズ， インク． シグナリングコンジュゲート及び使用法
US10866234B2 (en) 2015-03-13 2020-12-15 Sysmex Corporation Method for detecting analyte
JPWO2016147825A1 (ja) * 2015-03-13 2017-12-28 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
US11899016B2 (en) 2015-11-22 2024-02-13 Ventana Medical Systems, Inc. Methods of identifying immune cells in PD-L1 positive tumor tissue
JP2018536163A (ja) * 2015-11-22 2018-12-06 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１陽性腫瘍組織における免疫細胞を同定する方法
JP2017158497A (ja) * 2016-03-10 2017-09-14 コニカミノルタ株式会社 Ｆｉｓｈ染色方法
JPWO2017175523A1 (ja) * 2016-04-06 2019-02-14 コニカミノルタ株式会社 蛍光免疫染色法
WO2017175523A1 (ja) * 2016-04-06 2017-10-12 コニカミノルタ株式会社 蛍光免疫染色法
JP2020514701A (ja) * 2016-12-19 2020-05-21 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022169540A (ja) * 2016-12-19 2022-11-09 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP7438281B2 (ja) 2016-12-19 2024-02-26 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
JP2022500657A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
JP7455816B2 (ja) 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
JP2023538753A (ja) * 2020-08-28 2023-09-11 ヴェンタナ メディカル システムズ， インク． 検出可能な部分を含むコンジュゲート
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本

Also Published As

Publication number Publication date
US20130109019A1 (en) 2013-05-02
AU2011274369A1 (en) 2012-12-06
CA2800936A1 (en) 2012-01-05
WO2012003476A3 (en) 2012-05-03
WO2012003476A2 (en) 2012-01-05
EP2588443A2 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
JP2013531801A (ja) 標的検出のためのハプテンコンジュゲート
JP7000489B2 (ja) ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
JP6770150B2 (ja) 免疫組織化学およびｉｎ ｓｉｔｕハイブリダーゼーションのためのポリマー担体
US11906523B2 (en) Signaling conjugates and methods of use
WO2019120635A1 (en) Peptide nucleic acid conjugates
AU2018202287B2 (en) Haptens, hapten conjugates, compositions thereof and method for their preparation and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721